Precision medicine research at Karmanos comparing biomarker

A Barbara Ann Karmanos Cancer Institute clinical researcher and her team have received $16,000 to further research in precision medicine for breast cancer treatment. Common Citizen leadership delivered the check to Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams, in November 2023. Dr. Elayoubi and her team have made significant strides in studying biomarkers and tumor molecular characteristics that may predict sensitivity and

Halabi et al KCJ19n3 2021

Patient Stories

From Discovery to Clinical Application: The Role of Biomarkers in

Oncologist Perspectives on the Most Exciting Advancements in

Cancer Biomarkers: Powering Precision Medicine

Precision Oncology and Cancer Biomarkers: Issues at Stake and

Frontiers Biomarker-driven drug repurposing on biologically

Karmanos Cancer Institute on LinkedIn: #yourbestchance

Lasting bond and exceptional care through genetic counseling leads to rekindled friendship decades later

Considerations of Biomarker Application for Cancer Continuum in

Karmanos Cancer Institute

Cancer Epigenetics For Precision Medicine: Methods and Protocols

Preparing for a colonoscopy: The 3-day countdown to a clean colon

Frontiers Precision Medicine and the Role of Biomarkers of